We provide you with 20 years of free, institutional-grade data for TYRA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of TYRA. Explore the full financial landscape of TYRA stock.
| Reported Date | CIK | Ticker | Type |
|---|
Tyra Biosciences, Inc.(NASDAQ:TYRA) 
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatm...
Website: http://www.tyra.bio
Founded: 2018
CEO / Co-Founder: Todd Harris
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about TYRA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.